CA2535760A1 - Voies d'apicomplexan, inhibiteurs et administration de medicaments - Google Patents

Voies d'apicomplexan, inhibiteurs et administration de medicaments Download PDF

Info

Publication number
CA2535760A1
CA2535760A1 CA002535760A CA2535760A CA2535760A1 CA 2535760 A1 CA2535760 A1 CA 2535760A1 CA 002535760 A CA002535760 A CA 002535760A CA 2535760 A CA2535760 A CA 2535760A CA 2535760 A1 CA2535760 A1 CA 2535760A1
Authority
CA
Canada
Prior art keywords
gondii
triclosan
apicomplexan
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002535760A
Other languages
English (en)
Inventor
Rima L. Mcleod
Ernest J. Mui
Benjamin U. Samuel
Douglas G. Mack
Michael J. Kirisits
Paul A. Wender
Jonathan Rothbard
Brian Hearn
Craig W. Roberts
David W. Rice
Stephen P. Muench
Sean Prigge
Samantha A. Campbell
John R. Coggins
Fiona Roberts
Fiona L. Henriquez
Wilbur K. Milhous
Dennis E. Kyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2535760A1 publication Critical patent/CA2535760A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un gène Fab I d'apicomplexan et le gène pour la DAHP synthase dans <i>Toxoplasma gondii</i> et leurs enzymes codées constituent des moyens pour développer de façon rationnelle de nouvelles compositions inhibitrices, utiles dans la prévention et le traitement des maladies liées à l'apicomplexan. On peut, par exemple, utiliser le triclosan en tant que composé principal. L'administration d'inhibiteurs aux micro-organismes au moyen de polymères d'acides aminés courts est un nouveau procédé de traitement des infections actives et une nouvelle méthode pour acheminer des anti-microbiens jusqu'aux parasites latents enkystés. La voie de shikimate est cruciale pour la survie des parasites d'apicomplexan <i>Plasmodium falciparum</i>, <i>Toxoplasma gondii</i> et <i>Cryptosporidium parvum</i>. En raison de son absence chez les mammaliens, elle représente une cible thérapeutique intéressante. L'invention concerne aussi des gènes codant les eznymes de la voie de shikimate <i>T. gondii</i>. Des séquences supposées d'AOX ont été identifiées et séquencées à partir des souches de type 1 et de type 2 de <i>C. parvum</i>. Le gène code pour un polypeptide de 336 acides aminés et comprend une séquence de transit N-terminale similaire à celle présente dans des protéines ciblées sur les mitochondries d'autres espèces. L'oxydase alternative (AOX) est une autre cible des nouveaux agents anti-microbiens pour <i>C. parvum</i>.
CA002535760A 2002-08-15 2003-08-14 Voies d'apicomplexan, inhibiteurs et administration de medicaments Abandoned CA2535760A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40403302P 2002-08-15 2002-08-15
US60/404,033 2002-08-15
US43820503P 2003-01-06 2003-01-06
US60/438,205 2003-01-06
US46343203P 2003-04-16 2003-04-16
US60/463,432 2003-04-16
US47288703P 2003-05-23 2003-05-23
US60/472,887 2003-05-23
PCT/US2003/025571 WO2004016220A2 (fr) 2002-08-15 2003-08-14 Voies d'apicomplexan, inhibiteurs et administration de medicaments

Publications (1)

Publication Number Publication Date
CA2535760A1 true CA2535760A1 (fr) 2004-02-26

Family

ID=31892261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002535760A Abandoned CA2535760A1 (fr) 2002-08-15 2003-08-14 Voies d'apicomplexan, inhibiteurs et administration de medicaments

Country Status (4)

Country Link
EP (1) EP1534837A4 (fr)
AU (1) AU2003259848A1 (fr)
CA (1) CA2535760A1 (fr)
WO (1) WO2004016220A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969514B2 (en) 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
WO2006095837A1 (fr) * 2005-03-09 2006-09-14 National University Corporation Hokkaido University Structure lipidique membranaire capable de distribuer une substance cible a la mitochondrie
CN118750592A (zh) * 2024-09-06 2024-10-11 华南农业大学 一种缺失TgAROM基因的弓形虫减毒活疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403337B1 (en) * 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides
JP2002502376A (ja) * 1997-05-21 2002-01-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 生物学的膜を横切る輸送を増強するための組成物および方法
JP2003511068A (ja) * 1999-10-13 2003-03-25 パンセコ・アクティーゼルスカブ Ｐｎａを使用した遺伝子選択
DE60135157D1 (de) * 2000-12-21 2008-09-11 Rima W Mcleod Fab i und hemmung von apicomplexan-parasiten

Also Published As

Publication number Publication date
WO2004016220A2 (fr) 2004-02-26
WO2004016220A3 (fr) 2005-02-24
EP1534837A4 (fr) 2006-09-20
AU2003259848A1 (en) 2004-03-03
EP1534837A2 (fr) 2005-06-01

Similar Documents

Publication Publication Date Title
Morrissette et al. Dinitroanilines bind α-tubulin to disrupt microtubules
Sagaram et al. Structure-activity determinants in antifungal plant defensins MsDef1 and MtDef4 with different modes of action against Fusarium graminearum
Dittmann et al. Cyanobacterial toxins: biosynthetic routes and evolutionary roots
Roberts et al. Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target
Yang et al. Cyclase-associated protein cap with multiple domains contributes to mycotoxin biosynthesis and fungal virulence in Aspergillus flavus
Griffiths et al. A defect in ATP‐citrate lyase links acetyl‐CoA production, virulence factor elaboration and virulence in C ryptococcus neoformans
Robbins et al. The malaria parasite cyclin H homolog PfCyc1 is required for efficient cytokinesis in blood-stage Plasmodium falciparum
Stelter et al. The expression of a plant-type ferredoxin redox system provides molecular evidence for a plastid in the early dinoflagellate Perkinsus marinus
Geiser et al. Molecular pharmacology of adenosine transport in Trypanosoma brucei: P1/P2 revisited
Mavrianos et al. Mitochondrial two-component signaling systems in Candida albicans
Matesanz et al. The cloning and expression of Pfacs1, a Plasmodium falciparum fatty acyl coenzyme A synthetase-1 targeted to the host erythrocyte cytoplasm
Iizumi et al. Molecular cloning and characterization of ouabain-insensitive Na+-ATPase in the parasitic protist, Trypanosoma cruzi
CA2535760A1 (fr) Voies d&#39;apicomplexan, inhibiteurs et administration de medicaments
Martho et al. The glycerol phosphatase Gpp2: A link to osmotic stress, sulfur assimilation and virulence in Cryptococcus neoformans
US6737237B1 (en) Antimicrobial agents, diagnostic reagents, and vaccines based on unique Apicomplexan parasite components
Lu et al. Type I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structure
Maryam et al. The enigmatic role of fungal annexins: the case of Cryptococcus neoformans
Shen et al. Triintsin, a human pathogenic fungus-derived defensin with broad-spectrum antimicrobial activity
WO1998052972A1 (fr) Nouvelle proteine, son gene, reactifs induisant l&#39;apoptose et agents anticancereux
US20100151590A1 (en) Diagnosis and treatment of infectious diseases through indel-differentiated proteins
Jaremko Identifying Critical Interactions in the Unique Trypanosoma brucei 5S Ribonucleoprotein Complex and Their Role in Ribosome Biogenesis
Han et al. Transcriptional variation in Babesia gibsoni (Wuhan isolate) between in vivo and in vitro cultures in blood stage
Bishola Tshitenge Regulating a post-transcriptional regulator of gene expression, the RNA-binding protein 10, in Trypanosoma brucei
Morgan Characterization of a Potential Glucose Transporter in Trypanosoma brucei
Sharif In-Depth Analysis of Coat Protein Complex II Cargo Selectivity within the Early Secretory Pathway of African Trypanosomes

Legal Events

Date Code Title Description
FZDE Dead